Climb Bio Consensus Price Target Raised 21.88% to $28.41
The average one-year price target for Climb Bio (NASDAQGM:CLYM) has been revised to $28.41 / share from $23.31 (prior estimate dated August 25, 2026), an increase of 21.88%. These figures represent aggregate analyst targets compiled from multiple sources and do not constitute a recommendation orinvestment adviceby Fintel.
The latest analyst targets range from a low of $18.18 to a high of $42.00 / share. The average price target represents an increase of 95.15% from the closing price of $14.56 / share reported on September 14, 2026. The current median target increased to $27.03 from a prior median of $22.44, an absolute median change of $4.59. The current target range width is $23.82 compared to the prior width of $18.57.
This revision marks the 7th consecutive time the mean target has increased and represents a target change of +40.91% since the 90-day baseline date of June 8, 2026. Over the observed twelve-month period, the high mean target was $28.41 on September 15, 2026, and the low mean target was $9.18 on September 30, 2025.
For reference, Climb Bio's stock price closed at $14.56 on September 14, 2026 (one-week change -6.19% from a baseline close of $15.52 on September 4, 2026; one-month change -10.84% from a baseline close of $16.33 on August 14, 2026). In its latest earnings report on August 6, 2026, the company reported actual EPS of -0.18 versus an estimated EPS of -0.2178; both actual and estimated revenues were reported at $0.00.
Recent analyst actions include HC Wainwright & Co. maintaining a Buy grade and Oppenheimer maintaining an Outperform grade on September 8, 2026; B. Riley Securities reiterated Buy on September 4, 2026; and Baird maintained Outperform on September 3, 2026. As of September 1, 2026, the recommendation trend consisted of 10 strong buy, 10 buy, and 1 hold recommendations.
| Company | Target revision | Implied change |
|---|---|---|
| NewcelX | 0.00% | +606.63% |
| Lineage Cell Therapeutics | 0.00% | +424.30% |
| Rocket Pharmaceuticals | -8.11% | +156.49% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.